Previous close | 95.50 |
Open | 95.50 |
Bid | 96.21 x 45100 |
Ask | 101.21 x 45100 |
Day's range | 95.50 - 95.50 |
52-week range | 86.12 - 110.16 |
Volume | |
Avg. volume | 12,398 |
Market cap | 121.387B |
Beta (5Y monthly) | 0.41 |
PE ratio (TTM) | 24.61 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 4.07 (4.26%) |
Ex-dividend date | 13 May 2024 |
1y target est | N/A |
Eli Lilly (LLY) wins FDA approval for its Alzheimer's disease drug, Kisunla. (donanemab). Sanofi (SNY) and Regeneron's Dupixent gets approval for COPD in Europe.
The French public investment bank is in talks with "many funds" and may team up with the winning bidder for Sanofi's consumer health unit, Gonzalo was quoted as saying. Bpifrance confirmed Gonzalo had made the comments on Sanofi's consumer health unit and other potential investments during a briefing on Thursday.
(Bloomberg) -- Bpifrance SACA is looking at a potential investment in Sanofi SA’s consumer health unit as it eyes bigger health investments, according to its executive director Jose Gonzalo.Most Read from BloombergBiden’s Fourth of July Shrouded by Pressure to Drop 2024 BidKamala Harris Is Having a Surprise Resurgence as Biden’s Campaign UnravelsSingapore Couples Are Marrying Earlier to Buy Homes, Leading Some to RegretNewsom Shocks California Politics by Scrapping Crime MeasureHouse Democrats C